Ngenla is a medicine developed by Pfizer for the treatment of growth hormone deficiency. It is mainly used to treat growth hormone deficiency in children and in some cases in adults. Ngenla contains human growth hormone (somatropin) and helps regulate bone growth, body composition and metabolism in patients with growth hormone deficiency.
The active substance of Ngenla is somatrogon. Somatrogon is a long-acting growth hormone analog produced using recombinant DNA technology. It has the same effect as human growth hormone (hGH) and helps regulate growth and metabolism in individuals with growth hormone deficiency. Somatrogon is administered by injection under the skin once a week, making it easier to administer in the treatment of growth hormone deficiency.
The main differences between Ngenla (somatrogon) and Genotropin (somatropin) are as follows
Ngenla: Somatrogon is a long-acting growth hormone analog.
Genotropin: Somatropin is a recombinant human growth hormone.
Ngenla: Injections are given once a week.
Genotropin: Usually requires daily injection.
Ngenla is designed to be longer acting than somatropin.
Somatrogon is a long-acting growth hormone analog produced using recombinant DNA technology. It has a similar effect to Somatropin but has a longer lasting effect, so injections once a week are sufficient. Somatrogon was developed for children and adults with growth hormone deficiency and helps regulate growth and metabolism. It is especially used in the treatment of growth hormone deficiency and improves patient compliance with treatment.
